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ahis review summarizes publications on non–ST-segment
levation acute coronary syndromes (NSTE-ACS) from
une 2008 to May 2009. Table 1 lists trial acronyms.
pidemiology
ortality following acute myocardial infarction has de-
lined by approximately 30% over the past 2 decades (1),
lthough the burden of coronary heart disease (CHD)
emains high. This year, it is estimated, on average, approx-
mately 1 American will have an acute coronary event every
5 s, resulting in 1 death per minute (2). The prevalence of
STE-ACS is increasing relative to ST-segment elevation
yocardial infarction (STEMI) due to changes in the
istribution of risk factors in the population (e.g., older age,
redominance of females, higher rate of diabetes) (1), use of
reventative medications (3), and increasingly sensitive tro-
onin assays (4). Two risk factors heading in opposite
irections are smoking and obesity. Smoke-free legislation
ppears to have reduced hospitalization for ACS (5),
hereas the obesity-diabetes pandemic has resulted in a
isproportionate increase in non–ST-segment elevation
yocardial infarction (NSTEMI) among young patients
each 5 kg/m2 increase of body mass index is associated with
3-year decrease in age of first NSTEMI) (6).
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ur understanding of the pathophysiology of ACS continues
o improve, particularly with advances in imaging techniques
nd biomarkers. Two invasive imaging techniques—optical
oherence tomography and intravascular ultrasound—can
dentify vulnerable plaques with thin-capped fibroatheromas
TCFA) and positive remodeling in patients with ACS (7).
hese plaque morphologies have been associated with subse-
uent adverse cardiac events (8). Interestingly, different stres-
ors may cause a plaque to rupture in different locations (e.g.,
xertion: thick shoulder [9], diabetes: thin midportion [10]).
his raises the hope that information regarding plaque mor-
hology could be helpful in prioritizing risk factors and setting
reatment goals.
In addition to the well-known risk factors leading to
ipid-rich vulnerable plaques, a number of intriguing studies
ave linked nontraditional factors such as panic disorder
11), physical distress (12), and insufficient sleep (13) to
ncident CHD. Evaluation of both pharmacologic (e.g.,
ith serotonin reuptake inhibitors [14]) and nonpharmaco-
ogic therapies (e.g., use of music [15] and patient informa-
ion sheets [16]) directed at reducing anxiety, depression,
nd stress are needed.
Although plaque rupture and intraluminal obstruction are
he most common mechanisms underlying an ACS, in the
ASPAR study (17), nearly 25% of patients with ACS
rospectively undergoing coronary angiography did not have a
ulprit lesion. Furthermore, nearly one-half of these patients
ithout culprit lesions exhibited ischemic ST changes after
dministration of intracoronary acetylcholine, suggesting that
hese patients may benefit from therapies (e.g., calcium-
lockers, nitrates) directed at preventing spasm. Although the
otion of coronary artery spasm serving as one of the important
echanisms underlying ACS is not new (18), the findings of
he CASPAR study remind us that coronary artery endothelial
unction, in addition to vessel morphology, can play a critical role
n the development of ACS.
oninvasive Assessments
variety of noninvasive techniques in patients with NSTE-
CS have improved the ability to establish the diagnosis
nd provide accurate prognostication. Contrast-enhanced
omputed tomographic angiography (CTA) can identify
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October 13, 2009:1544–55 Year in NSTEMIeatures of a vulnerable plaque (positive remodeling, low
laque density consistent with lipid-rich lesions), and in a
rospective study (19), categorized patients into high risk
22%), intermediate risk (6.5%), or low risk (0.5%) of
eveloping an ACS event over the next 27 months based on
he presence of 2, 1, or none of these features. By imaging
laque morphology CTA permits greater diagnostic sensi-
ivity beyond that possible with the evaluation of calcium-
coring alone (20).
In the MESA study (21), the left ventricular mass-to-
olume ratio measured using cardiac magnetic resonance
maging (MRI) was strongly associated with incident CHD.
n another study of MRI in NSTE-ACS, diagnostic accu-
acy rose from 84% using conventional MRI alone to 93%
sing an MRI protocol that included T2-weighted imaging,
ssessment of left ventricular (LV) wall thickness, and
elayed enhancement (22). Edema detected on T2-
eighted images in dogs with transient coronary occlusions
orrelated with acute ischemic injury prior to necrosis (23),
hus representing another potentially useful marker identi-
able by MRI early following symptom onset.
Both coronary CTA (24) and magnetocardiography (25)
re also helpful in rapidly establishing the diagnosis of
STE-ACS, with the former having high negative and the
atter high positive predictive value. In the ROMICAT trial
f patients with acute chest pain and low-intermediate risk
f ACS, 64-slice coronary CTA was able to identify the
0% of patients who were free of coronary artery disease and
cronymsTable 1 Acronyms
Acronym
ACUITY Acute Catheterization and Urgent Intervention Triage Strategy
APPRAISE Apixaban for Prevention of Acute Ischemic and Safety Events
ATLAS ACS Anti-Xa Therapy to Lower cardiovascular events in addition to
BRIEF-PCI Brief Infusion of Eptifibatide Following Percutaneous Coronary
CASPAR Coronary Artery Spasm in Patients with Acute Coronary Syndr
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients sup
CURRENT Clopidogrel Optimal Loading Dose Usage to Reduce Recurren
DISPERSE Dose confirmation Study assessing anti-Platelet Effects of AZ
EARLY ACS Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Eleva
GRACE Global Registry of Acute Coronary Events
GRAVITAS Gauging Responsiveness with a VerifyNow assay—Impact on
IMPROVE-IT IMProved Reduction of Outcomes: Vytorin Efficacy Internation
ISAR-REACT Intracoronary Stenting and Antithrombotic Regimen: Rapid Ea
MERLIN Metabolic Efficiency With Ranolazine for Less Ischemia in No
MESA Multi-Ethnic Study of Atherosclerosis
OASIS Optimal Antiplatelet Strategy for InterventionS
PROVE IT Pravastatin or Atorvastatin Evaluation and Infection Therapy
ROMICAT Rule Out Myocardial Infarction using Computer Assisted Tomo
SYNERGY Superior Yield of the New Strategy of Enoxaparin, Revascular
TIMACS TIMing of Intervention in patients with Acute Coronary Syndro
TIMI Thrombolysis In Myocardial Infarction
TRITON Trial to Assess Improvement in Therapeutic Outcomes by Opt
CC/AHA  American College of Cardiology/American Heart Association.id not have ACS (26). ATwo studies evaluated the ability of continuous electro-
ardiography (cECG) to predict future ischemic events. In
ERLIN-TIMI 36, 20% of 6,355 patients experienced at
east 1 episode of ischemia on cECG within 7 days of
STE-ACS, and such patients experienced a nearly 3-fold
ncrease in mortality and 2-fold increase in recurrent myo-
ardial infarction (MI) over the next year (27). Furthermore,
igh morphologic variability in the shape of the entire heart
eat signal on 24-h cECG monitoring within 48 h post
STE-ACS in DISPERSE-2 TIMI 33 trial was associated
ith a marked increase in the risk of death at 90 days
adjusted hazard ratio [HR]: 6.9, p  0.001) (28).
iomarkers
n American Heart Association (AHA) scientific state-
ent on the criteria for evaluation of novel markers of
ardiovascular risk (29) set forth standards for the critical
ppraisal of risk assessment methods. Among the key
oncepts identified were: 1) the need to demonstrate the
egree to which a novel marker adds to the prognostic
nformation provided by standard risk markers (both in
erms of discrimination and accuracy); 2) the clinical value
f the marker as measured by the effect on patient manage-
ent and outcome; and 3) the cost-effectiveness of the
arker.
Table 2 highlights a selected sample of biomarkers that
ave been associated with the development of NSTE-ACS
30–34) or prediction of future events following NSTE-
Trial Name
n with or without thienopyridine therapy in Subjects with Acute Coronary Syndrome
ention
Adverse outcomes with Early Implementation of the ACC/AHA Guidelines
Ts
vs. clopidogrel in non-ST segment Elevation myocardial infarction
cute Coronary Syndrome
bosis and Safety
l
tion for Coronary Treatment
levation Acute Coronary Syndrome
y
, and Glycoprotein IIb/IIIa Inhibitors
Platelet Inhibition With PrasugrelAspiri
Interv
ome
press
t EveN
D6140
tion A
Throm
al Tria
rly Ac
n–ST-E
graph
ization
mes
imizingCS (35–37) published in the past year.
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nticoagulants. Additional analyses from prior trials in-
estigating enoxaparin, fondaparinux, and bivalirudin, as
ell as 2 phase II studies with oral factor Xa inhibitors
rivaroxaban, apixaban) were highlighted in the past year.
hese data provide additional support for the use of
lternatives to unfractionated heparin (UFH) and vitamin K
ntagonists (e.g., warfarin).
Patients age 75 years enrolled in the SYNERGY trial
UFH vs. enoxaparin in high-risk NSTEACS patients
anaged with an early invasive strategy) experienced higher
ates of adverse events compared to younger patients.
owever, the relative efficacy and safety of enoxaparin
ompared with UFH were similar across age groups (38).
Fondaparinux, an indirect, selective, reversible, parenteral
actor Xa inhibitor, demonstrated similar efficacy and less
leeding than enoxaparin regardless of the level of risk of
atients with NSTE-ACS in the OASIS-5 study (39). In a
ombined analysis of the OASIS-5 and -6 studies, fondapa-
inux also reduced the net composite of bleeding and
schemic events compared with a heparin-based strategy
ith either an invasive or conservative management strategy
40). A cost analysis from the OASIS-5 study estimated
hat fondaparinux would save an average of $547 (95%
onfidence interval [CI]: $207 to $924) per patient through
80 days, and over the longer term, was dominant (i.e.,
ondaparinux was less costly and improved quality-adjusted
mportant New Data With BiomarkersTable 2 Important New Data With Biomarkers
Possible Mechanism
Markers predicting the development of ACS
von Willebrand factor (32) Mediates platelet adhesion, aggrega
stress), and stabilizes factor VIIIc
Erythrocyte-membrane bound
interleukin-8 (34)
Increases inflammatory response upo
erythrocyte membrane during intra
hemorrhage
Platelet collagen receptor GP VI (30) Enhances platelet aggregability
Platelet-bound stromal-cell–derived
factor-1 (33)
May play a role in vascular and myoc
or regeneration
Linoleic acid (31) Varies inversely with low-density lipop
undefined mechanism
Trans isomer of oleic acid (31) Unfavorable effects on lipid profile, e
function, and inflammatory marke
Markers predicting prognosis in patients with ACS
Thrombus precursor protein (36) Reflects enhanced systemic activatio
coagulation system
Chromogranin A (35) Negative inotropy, induction of apopt
catecholamine secretion, vasodilat
Free plasma homocysteine (37) Causes endothelial damage and dysf
CS  acute coronary syndrome; CHF  congestive heart failure; GP  glycoprotein; HR  hazarife-years) under most scenarios (41). $The oral direct factor Xa inhibitors rivaroxaban and apixa-
an were studied in 2 similarly designed phase II placebo-
ontrolled dose-ranging studies of patients with ACS known
s ATLAS ACS-TIMI 46 (42) and APPRAISE (43). In both
rials, the factor Xa inhibitors were associated with dose-related
ncreases in bleeding compared with placebo (particularly on a
ackground of aspirin with clopidogrel), and a tendency
oward fewer ischemic events (Fig. 1). In the APPRAISE trial,
he 2 highest dosages of apixaban (10 mg twice daily, 20 mg
nce daily) were prematurely terminated due to excess major
leeding.
In the ACUITY trial, bivalirudin, a direct-acting anti-
hrombin (with or without glycoprotein IIb/IIIa inhibitor)
as associated with a similar rate of stent thrombosis
hrough 30 days as heparin with a glycoprotein IIb/IIIa
nhibitor (1.6% vs. 1.1%, p  0.28) (44). Overall, the rates
f mortality alone and an ischemic composite through 1 year
ith bivalirudin-based strategies in patients undergoing
ercutaneous coronary intervention (PCI) were similar to
hose with heparin and glycoprotein IIb/IIIa inhibitors (45).
lthough the drug costs are higher in bivalirudin-based
trategies, an economic analysis of aggregate hospital and
0-day costs demonstrated lowest costs with bivalirudin
onotherapy compared with several alternative strategies
hat included glycoprotein IIb/IIIa inhibitors (whether ad-
inistered routinely early or selectively in the catheteriza-
ion laboratory) in combination with either UFH or biva-
irudin (mean differences in costs ranged from $123 to
Major Findings
t high shear OR: 3.0 for the fourth quartile compared with first quartile in
patients developing ACS
ase from 1 SD increase was associated with 5.1-fold higher odds of
having ACS (compared with chronic stable angina), adjusted
for baseline characteristics and other markers
Mean fluorescence intensity above the cutoff of 18.6 (i.e., an
elevated level of surface expression of GP VI) had a 1.4-fold
relative risk for ACS
remodeling 1.4-fold higher level in patients with ACS compared with stable
angina
, other 1 SD decrease was associated with a 3-fold increase in the
odds of being a case (ACS) compared with controls
lial 1 SD increase was associated with an OR of 1.2 or being a
case (ACS) compared with controls
e Elevated levels independently associated with increased risk of
death, reMI, or recurrent ischemia (HR: 1.5) and death or MI
(HR: 1.6), adjusted for baseline characteristics and other
biomarkers
hibition of 1 SD increase associated with increases in mortality (1.3-fold),
CHF hospitalizations (1.2-fold) after adjustment for
conventional cardiovascular risk markers
n Levels 4.11 mol/l (highest quintile) was independently
associated with increased risk of cardiovascular death, MI,
or stroke (HR: 2.3) after a median follow-up of 2.7 years
MI  myocardial infarction; OR  odds ratio; reMI  recurrent infarction.tion (a
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October 13, 2009:1544–55 Year in NSTEMIivalirudin monotherapy) (46). If bivalirudin monotherapy
s selected, it appears important to administer clopidogrel
efore or within 30 min of PCI to ensure protection from
eriprocedural ischemic complications (47).
In the ISAR-REACT 3 trial (48), bivalirudin and UFH
ere compared in patients with stable or unstable angina
ho had received clopidogrel 600 mg2 h prior to PCI and
o glycoprotein IIb/IIIa inhibitor. In this setting, bivaliru-
in and UFH achieved similar net clinical benefit (ischemic
nd bleeding complications: 8.3% vs. 8.7%, p  0.57). A
ower rate of major bleeding with bivalirudin (3.1% vs.
.6%, p  0.008) was largely offset by a numeric increase in
schemic events (death, MI, urgent target-vessel revascular-
zation due to myocardial ischemia: 5.9% vs. 5.0%, p 
.23). These data, when interpreted in the context of prior
tudies with heparin and bivalirudin with versus without
lycoprotein IIb/IIIa inhibitors, demonstrate a reduction in
leeding with bivalirudin monotherapy that is counterbal-
0%
5%
10%
15%
20%
pbo 2.5 mg
BID
10 mg
QD
pbo 5 mg 10 mg 20 mg
Aspirin only background therapy
Apixaban Rivaroxaban
0%
2%
4%
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pbo 2.5 mg BID 10 mg QD pbo All
Rivaroxaba
Quadruple Ischemic Endpoint
Primary Bleeding End Point
Apixaban
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B
Figure 1 Bleeding and Ischemic Complications in 2 Phase II Tr
(A) Rates of major or clinically-relevant nonmajor bleeding in the APPRAISE trial (4
10 mg once daily [QD]) on a background of aspirin without (left) and with clopidog
ing, TIMI minor bleeding, or bleeding requiring medical attention in the ATLAS-TIMI
rates of the quadruple efficacy end point (death, myocardial infarction, severe recu
infarction, or ischemic stroke) are shown on the left and right for the same 2 stud
in the APPRAISE trial, whereas all-cause mortality was used in ATLAS-TIMI 51.nced by an increase tendency of ischemic complications uhen glycoprotein IIb/IIIa inhibitors are omitted (even
hen 600 mg of clopidogrel is administered).
ntiplatelet agents. A large number of publications in the
ast year reported on the limitations of currently available
latelet inhibitors and the promise of novel antiplatelet
gents. Identification of patients with a suboptimal anti-
latelet response is important to minimize recurrent events
49,50). For example, stent thrombosis is associated with a
igh rate of mortality or recurrent ST-segment elevation at
0 days (18%) and at 3 years (28%) (51). Patients who either
iscontinue clopidogrel (52) or exhibit residual platelet
eactivity (49) are at highest risk for stent thrombosis. In
ddition, patients with poor response to chronic clopidogrel
herapy also appear to be at risk for other ischemic compli-
ations such as MI (53). Factors that are associated with
uboptimal response to clopidogrel include patient charac-
eristics (e.g., advanced age, increased body mass index,
iabetes mellitus) (54), presence of aspirin resistance (54),
pbo 2.5 mg
BID
10 mg
QD
pbo 5 mg 10 mg 15 mg 20 mg
Aspirin + clopidogrel background therapy
Apixaban Rivaroxaban
pbo 2.5 mg BID 10 mg QD pbo All
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Triple Ischemic Endpoint
Apixaban
f Oral Factor Xa Inhibitors
shown for the placebo (pbo) and 2 doses of apixaban (2.5 mg twice daily [BID],
ht). Similarly, rates of Thrombolysis In Myocardial Infarction (TIMI) major bleed-
al (42) are shown for placebo and 4 ascending doses of rivaroxaban. (B) The
schemia, or ischemic stroke) and triple efficacy end point (death, myocardial
ote: cardiovascular mortality was included as part of the composite end pointsn
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Year in NSTEMI October 13, 2009:1544–55alcium-channel blockers (56), and polymorphisms of the
epatic cytochrome P450 (CYP) enzymes (57).
Clopidogrel is a prodrug that requires activation by
YP-dependent hepatic enzymes. Polymorphisms of the
YP2C19 (and also CYP3A4) genes encoding these en-
ymes may result in loss of function (i.e., less inhibition of
denosine-induced platelet activation). Therefore, such car-
iers are at increased risk for ischemic events compared with
atients with the normally functioning wild-type allele (Fig.
). In contrast, prasugrel, a novel thienopyridine that does
ot require hepatic activation by CYP-dependent enzymes,
s unaffected by these polymorphisms (58).
Three approaches to manage hyporesponse to clopidogrel
hat are being investigated are: 1) administration of higher
oses of clopidogrel; 2) use of drugs with more effective
GY12 antagonism; and 3) inhibition of other platelet
eceptors. One trial of 256 patients with NSTE-ACS did
ot show any difference (HR: 1.00, p  0.99) in ischemic
omplications between 600 mg and 300 mg of clopidogrel
oading pre-PCI. However, only 33 events were observed in
his underpowered trial (59). The much larger (n  25,087)
URRENT-OASIS 7 trial (60) comparing 2 different
egimens of clopidogrel (load/maintenance dose regimens of
00/75 mg vs. 600/150 [1 week] to 75 mg) and aspirin (75
o 100 mg vs. 300 to 325 mg) in a 2  2 design is due to
eport results this year. Additional data with higher-dose
lopidogrel are also forthcoming from the GRAVITAS trial
61), which is randomizing patients with stable angina or
STE-ACS undergoing drug-eluting stent implantation
nd who have high residual platelet reactivity to either
8.0
15.3
2.9
12.1
21.5
10.9
0
5
10
15
20
25
Mega et al. Simon et al. Collet et al.
Wild Type
Polymorphism
Ev
en
t R
at
e 
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)
Figure 2
Rates of Ischemic Complications in Patients
Receiving Clopidogrel With and Without
CYP2C19 Polymorphisms
The light blue bars represent the event rates for patients with the wild-type
allelic pattern of CYP2C19, whereas the dark blue bars are carriers of 1 or
more of the polymorphisms associated with loss of function. (In the study by
Simon et al. [116], patients carrying any 2 CYP2C19 loss-of-function alleles
[*2, *3, *4, or *5] are compared with those with none). The end points for the
3 studies were as follows: Mega et al. (57): rate of cardiovascular death, myo-
cardial infarction, or stroke over a median of 15 months; Simon et al. (116):
death, myocardial infarction, or stroke at 1 year; Collet et al. (117): annualized
rate of cardiovascular death, myocardial infarction, or urgent revascularization.tandard maintenance dosing of clopidogrel (75 mg daily) or Tigh-dose therapy (additional loading followed by 150 mg
aily for 6 months).
Alternative PGY12 inhibitors in development include the
ral drugs prasugrel and ticagrelor, the intravenous agent
angrelor, and elinogrel (PRT060128); the latter is being
eveloped in both oral and intravenous formulations (62).
rimary results of the TRITON-TIMI 38 trial, which
ompared prasugrel to clopidogrel, were covered in last
ear’s report (63). New data in the past 12 months with
rasugrel include analyses that demonstrated the ability of
rasugrel, compared with clopidogrel, to reduce recurrent
ardiovascular events by 45% (p 0.016) and cardiovascular
eath by 54% (p 0.008) following an initial nonfatal event
64). Also, the net treatment benefit with prasugrel, com-
ared with clopidogrel, tended to be even greater among
iabetic patients (65), which appears to be related to
ncreased levels of active metabolites observed with prasug-
el relative to clopidogrel among diabetic compared with
ondiabetic patients (66). The long-awaited results of 3
hase III trials—PLATO (A Study of Platelet Inhibition
nd Patient Outcomes) (67) (investigating ticagrelor in pa-
ients with NSTE-ACS and STEMI) and 2 CHAMPION
Cangrelor Versus Standard Therapy to Achieve Optimal
anagement of Platelet Inhibition) studies (investigating
angrelor in patients undergoing PCI)—are expected to be
nveiled in full later this year. Top-line results announced in
ress releases reported that ticagrelor reduced the composite
ate of vascular death, nonfatal MI, or nonfatal stroke
ompared with clopidogrel in the PLATO trial (68),
hereas both CHAMPION trials were terminated early
ue to lack of efficacy with cangrelor (69). Finally, prelim-
nary results in patients with high residual platelet reactivity
espite clopidogrel, demonstrated that a single 60-mg oral
ose of elinogrel was effective in profoundly inhibiting
latelet function using 4 different functional assays (70).
urther studies with elinogrel are underway.
A third option to overcome hyporesponsiveness to clopi-
ogrel is to achieve more effective platelet inhibition
hrough inhibition of a target other than the PGY12
eceptor. Cilostazol, a selective phosphodiesterase inhibitor,
as superior to 150 mg of clopidogrel daily in reducing the
ate of high post-treatment platelet reactivity in patients
ith ACS undergoing PCI who were hyporesponsive to a
00-mg clopidogrel loading dose (71). This finding may
xplain why cilostazol, when added to aspirin and clopi-
ogrel, reduced the primary composite of cardiac death,
onfatal MI, stroke, or target vessel revascularization at 1
ear from 15.1% to 10.3% (p  0.011) without increasing
leeding compared with standard dual antiplatelet therapy
72). Ongoing studies with 2 selective platelet protease-
ctivated receptor (PAR)-1 antagonists are exploring the
fficacy and safety of these novel agents in patients with
CS (73). Antagonism of the PAR-1 receptor on the
latelet surface interferes with the cellular actions of throm-
in, the most potent known physiologic agonist of platelets.
hus, PAR-1 antagonists exert an antiplatelet effect when
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October 13, 2009:1544–55 Year in NSTEMIhrombin-stimulated platelet activation is present. Since
hey do not interfere with collagen or ADP-induced platelet
ctivation, or with fibrin generation by thrombin, PAR-1
ntagonists may be less disruptive to normal hemostasis
ompared with other potent antiplatelet agents.
Two randomized trials explored alternative dosing regi-
ens with eptifibatide, a reversible intravenous glycoprotein
Ib/IIIa inhibitor. In the BRIEF-PCI trial (74), the stan-
ard 18-h infusion of eptifibatide was compared with an
bbreviated infusion of 2 h. There were no differences in
eriprocedural myonecrosis or clinical ischemic events
hrough 30 days between the 2 treatment groups, whereas
leeding was reduced from 4.2% to 1.0% (p  0.02) with
he shorter infusion.
In the EARLY ACS trial (75), a strategy of early, routine
ouble-bolus eptifibatide followed by an infusion was com-
ared with a strategy of initial placebo followed by provi-
ional eptifibatide (at the physician’s discretion) just prior to
CI in 9,492 patients with high-risk NSTE-ACS under-
oing angiography at 12 to 96 h. Routine early eptifibatide
as not superior to delayed provisional use and increased
he odds of major bleeding and red-cell transfusions by 42%
p 0.015) and 31% (p 0.001), respectively (Fig. 3). The
ata from EARLY ACS do not support routine upstream
se of eptifibatide, but additional analyses are ongoing to
etermine whether specific high-risk groups of patients with
STE-ACS may benefit from such a strategy. Taken
ogether, these 2 trials suggest that a shorter infusion of
ptifibatide initiated just prior to PCI reduces bleeding and
ould become the preferred regimen, provided that similar
linical efficacy to the standard 18- to 24-h infusion post-
10.0%
12.3%
3.4%
9.3%
11.2%
5.7%
0%
5%
10%
15%
Primary Endpoint at
96 hours
Secondary Endpoint
at 30 days 
TIMI Major/Minor
Bleeding at 120h
Delayed Provisional
Early Routine
N = 4722N = 4684 
OR 0.89 (0.79, 1.01)
P = 0.072
N = 4684  N = 4722  
OR 1.75 (1.43, 2.13)
P < 0.001
OR 0.92 (0.80, 1.06)
P = 0.23
N = 4643 N = 4686 
Figure 3 Major Efficacy and Safety
Results in the EARLY ACS Trial
Rates of the primary efficacy composite end point (death, myocardial infarction,
recurrent ischemia leading to urgent revascularization, or thrombotic bailout) at
96 h, key secondary efficacy composite (death or myocardial infarction) at 30
days, and the primary safety end point (TIMI major bleeding) are shown for a
delayed, provisional use of eptifibatide just prior to percutaneous coronary
intervention (blue) versus the routine early administration of eptifibatide (red).
OR  odds ratio; other abbreviations as in Figure 1.CI could be demonstrated in an adequately powered study.
tleeding complications of antithrombotic therapy. Nu-
erous publications continue to explore the relationship
etween bleeding and adverse outcomes, as well as strategies
o reduce bleeding complications of antithrombotic thera-
ies and invasive procedures in ACS. Analyses from 2 trials
RUSADE Bleeding Risk Scorestimating In-Hospital Major BleedingTable 3 CRUSADE Bleeding Risk ScoreEstimating In-Hospital Major Bleeding
Predictor Score
1. Baseline hematocrit, %
31 9
31–33.9 7
34–36.9 3
37–39.9 2
40 0
2. Creatinine clearance,* ml/min
15 39
15–30 35
30–60 28
60–90 17
90–120 7
120 0
3. Heart rate, beats/min
70 0
71–80 3
81–90 6
101–110 8
111–120 10
121 11
4. Sex
Male 0
Female 8
5. Signs of CHF at presentation
No 0
Yes 7
6. Prior vascular disease†
No 0
Yes 6
7. Diabetes mellitus
No 0
Yes 6
8. Systolic blood pressure, mm Hg
90 10
91–100 8
101–120 5
121–180 1
181–200 3
201 5
Risk of Bleeding
Total Score (Range 1–100) Predicted Risk of Bleeding
20 (very low) 3.1%
21–30 (low) 5.5%
31–40 (moderate) 8.6%
41–50 (high) 11.9%
50 (very high) 19.5%
Creatinine clearance was estimated with the Cockcroft-Gault formula. †Prior vascular disease
as defined as history of peripheral artery disease or prior stroke. To calculate the CRUSADE
leeding score, total the points associated with the above 8 factors and use the bottom part of the
able to predict the risk of bleeding (see text for details).
CHF  congestive heart failure.
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Year in NSTEMI October 13, 2009:1544–55oncluded that bleeding was closely associated with an
ncrease in fatal and nonfatal adverse outcomes (76,77),
lthough assessing causality is extremely challenging given
he complex relationships that exist between bleeding,
ntithrombotic therapies, ischemia, and invasive procedures.
ndeed, there may be multiple mechanisms by which bleed-
Figure 4 Hazard Ratios for the Primary and Secondary Outcome
Panel A shows hazard ratios for the composite primary outcome of death, myocar
intervention group, in selected subgroups of patients. Panel B shows hazard ratio
ischemia in the same subgroups. The size of the squares is proportional to the si
of Acute Coronary Events. Reproduced with permission from Mehta et al. (95).ng contributes to poor outcomes, such as the development hf ischemia due to supply–demand mismatch during bleed-
ng and the premature discontinuation of oral antiplatelet
herapy that occurs in response to the bleeding (73).
The relationship between the use of thienopyridines and
erioperative bleeding remains controversial. More judi-
ious use of transfusions (e.g., changing the transfusion
Pre-Specified Subgroups in the TIMACS Study
arction, or stroke in the early-intervention group, as compared with the delayed-
e composite secondary outcome of death, myocardial infarction, or refractory
he corresponding subgroup. CI  confidence interval; GRACE  Global Registrys in
dial inf
s for th
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October 13, 2009:1544–55 Year in NSTEMIbetter balance between risk and benefit (78). Fortunately,
eversible thienopyridines may prove to be safer in patients
ho may need coronary artery bypass grafting (CABG). In
he DISPERSE-TIMI 33 trial, the reversible PGY12 in-
ibitor ticagrelor was associated with less bleeding post-
ABG compared with clopidogrel (79), an observation that
as most evident when the drugs were continued until 5
ays before CABG.
Efforts to reduce bleeding have included modifications of
he medical therapies and access site management. Greater
ttention to appropriate dose adjustment of UFH (80),
voidance of concomitant nonsteroidal anti-inflammatory
rugs, which increase the risk of gastrointestinal bleeding
81), and efforts to develop safer anticoagulant regimens,
uch as bivalirudin, fondaparinux, and low-dose UFH (82),
ay also reduce bleeding.
A validated risk score (Table 3) that predicts major in-
ospital bleeding was developed from the CRUSADE registry
83). By summing points assigned to 8 readily available clinical
actors, patients can be classified into 1 of 5 bleeding categories
ith predicted bleeding risks ranging from very low (3.1%) to
ery high (19.5%) (c-statistic  0.71).
Two additional factors deserve consideration in the eval-
ation of bleeding risk. First, thrombocytopenia, even if
ild (i.e., 150,000/mm3 or 50% decline from baseline)
s a common complication in ACS and is associated with
ncreased bleeding, mortality, and ischemic complications
84,85). Thus, antithrombotic therapies that increase the
isk of thrombocytopenia may have an even greater propen-
ity for increased bleeding. Second, with the aging of the
opulation, more patients with ACS experience atrial fibril-
ation or flutter requiring so-called triple antithrombotic
herapy with aspirin, clopidogrel, and an oral anticoagulant
86), placing them at 9-fold increased odds for bleeding
ompared with those on dual antiplatelet therapy (87).
ntervention. Since this topic has been reviewed in the
ajor Changes in the 2008 ACC/AHA Performance Measures ReleTable 4 Major Changes in the 2008 ACC/AHA Performance M
2006 Measure 2008 Measure
Beta-blocker at arrival — Delet
Lipid-lowering therapy
at discharge
Statin at discharge Spec
del
LD
— Evaluation of left ventricular function New
— Referral to cardiac rehabilitation New
— Excess dosing of heparin,
enoxaparin, glycoprotein IIb/IIIa
inhibitors
New
— Anticoagulant dosing protocol New
— Anticoagulant error tracking system New
— Clopidogrel at discharge New
A test measure is an area worthy of assessment, but for reasons related to the strength of evidence
eporting. Adapted from Krumholz et al. (115).
ACC  American College of Cardiology; AHA  American Heart Association; LDL-C  low-densiYear In Interventional Cardiology” (88), we provide below 2few of the key highlights pertaining to patients with
STE-ACS.
With the majority of studies in the past 15 years showing
etter outcomes with an invasive strategy over medical
anagement, the current debate has shifted to the compar-
son of a strategy of early, routine use of angiography with
he less costly alternative of selective, deferred use (89).
isadvantages of the latter strategy include the potential for
eterioration of left ventricular function while awaiting
oronary angiography (90), and longer delays (91) or even
ischarge without angiography (92) in the highest risk
atients such as those with congestive heart failure (93) or
enal dysfunction (94).
Two studies published in the past year (95,96) failed to
how a significant reduction in their primary composite
schemic end points with an immediate invasive strategy
ompared with delayed angiography, and a third small study
eported higher rates of periprocedural necrosis with imme-
iate angiography (96). In the largest of the three trials (95),
arly coronary angiography (median 14 h after randomiza-
ion) and delayed intervention (median 50 h) achieved
imilar rates of the primary composite of death, MI, and
troke at 6 months (9.6% vs. 11.3%, HR: 0.85 [95%
onfidence interval: 0.58 to 1.06], p 0.15). However, early
ngiography was associated with a 28% reduction in the
econdary end point of death, MI, or refractory ischemia,
nd also reduced the primary composite end point in the
ne-third of patients at highest risk (GRACE risk score
140) (Fig. 4).
Several new angiographic observations have added to our
nderstanding of the prognosis with PCI. First, because
schemia in the left circumflex territory is not well repre-
ented on the standard 12-lead ECG, the proportion of
atients with a culprit lesion in the circumflex is higher
mong patients with NSTE-ACS than with STEMI (97).
related observation was that an occluded artery (incidence
to Patients With NSTE-ACSes Relevant to Patients With NSTE-ACS
Change Rationale
formance measure Increased complexity of decision making and
controversy about net benefit
atin only and
quirement that
100 mg/dl
Most recent guidelines support use of statins in the
absence of contraindications, regardless of
baseline LDL-C and diet
ance measure Determines prognosis and drives treatment decisions
ance measure Current guidelines recommend cardiac rehabilitation/
secondary prevention programs for patients with MI
easures* Recommended doses are well established; however
recent data suggest that excess dosing in patients
with ACS is common
easure* As above
easure* As above
easure* Recent data demonstrate significant variability in use
among medically managed patients
ility of measurement, or other considerations is not considered suitable for accountability or public
rotein cholesterol; NSTE  non–ST-elevation; other abbreviations as in Table 2.vanteasur
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ified st
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Year in NSTEMI October 13, 2009:1544–55upplying the posterolateral wall, consistent with the pres-
nce of an undiagnosed “true posterior” MI. This suggests a
arge unmet need for better methods to detect transmural
nfarction in the posterolateral wall, such as may be possible
ith body surface mapping (98). Lastly, impaired microvas-
ular flow post-PCI is also common in patients with
STE-ACS and can be predicted from the presence of
ncreased lipids in the culprit plaque as visualized by
re-procedural optical coherence tomography (99). Thus,
etailed evaluation of the culprit lesion and flow pre- and
ost-PCI may identify patients who require more aggres-
ive adjunctive therapies to reduce the risk of subsequent
omplications.
ipids. In patients with ACS, current guidelines recom-
end early initiation of statin therapy to lower the low-
ensity lipoprotein cholesterol (LDL-C) level to well below
00 mg/dl (and preferably to 70 mg/dl). In 2 recent
tudies utilizing intravascular ultrasound imaging, aggres-
ive statin therapy regressed coronary artery disease follow-
ng ACS (100), particularly when an LDL-C 70 mg/dl
as achieved (101). In addition, high-dose atorvastatin
ormalized the circulating levels of prostaglandin E2 and
etalloproteinase-9 activity in patients with NSTE-ACS,
hereby reversing the plaque destabilizing effects resulting
rom elevated levels of these inflammatory mediators (102).
hese findings support the notion of using even more
ntensive lipid-lowering therapies post-ACS, as is being
valuated in the IMPROVE-IT trial (103), which is de-
igned to achieve an LDL of 50 to 55 mg/dl with the
ombination of ezetimibe and simvastatin. Although this is
ow approaching the level of LDL-C in newborns, analyses
rom the PROVE IT-TIMI 22 trial demonstrated contin-
ed benefit of intensive lipid lowering (compared with
tandard therapy) among patients with baseline LDL-C
alues as low as 66 mg/dl (104,105).
In addition to the benefits observed with achieving lower
DL-C levels post-ACS, other studies suggest targeting
-reactive protein (106), high-density lipoprotein choles-
erol (107), and lipoprotein-associated phospholipase A2
ay further improve outcomes. These additional markers
ay be identifying other adverse processes (e.g., inflamma-
ion, endothelial dysfunction, plaque instability) that are not
ompletely addressed by dramatic lowering of the LDL with
tatins.
uality of Care
se of evidence-based medical therapies continues to in-
rease with implementation of guideline-based critical care
athways (108), even during weekends and holidays with
educed staffing (109). However, there remain subgroups of
atients, such as those with low-level troponin elevation
110), renal dysfunction (111), and multiple medical comor-
idities (112), in whom guideline therapies are not opti-
ally administered. Furthermore, there is an inverse rela-ionship between the amount of copayment and adherenceo outpatient prescriptions (113), confirming that these
atients represent a particularly vulnerable group. In addi-
ion, pre-authorization programs serve as a barrier for
atients to receive timely access to some proven therapies. In
n analysis of patients age 65 years with acute MI who
nderwent PCI in Ontario, Canada, between April 1, 2000,
nd March 31, 2005, removal of a prior-authorization
rogram for clopidogrel in 2003 increased the rate of
lopidogrel use within 30 days (from 35% to 88%) and
hortened the time to first dispensed dose (from 9 days to 0
ays) (114). More importantly, the adjusted 1-year compos-
te of death, recurrent MI, PCI, and CABG declined from
5% to 11% (p  0.02). We continue to endorse wider
ccess for all patients to evidence-based therapies that have
een demonstrated to improve clinical outcomes.
We end this year’s review by summarizing in Table 4 the
ajor changes to the ACC/AHA 2008 Performance Mea-
ures as they apply to patients with NSTE-ACS (115).
iven the new information summarized in this year’s review
nd the large number of ongoing studies nearing comple-
ion, it can be anticipated that future guidelines and perfor-
ance measures in NSTE-ACS will require updating in the
ext 2 years.
eprint requests and correspondence: Dr. Eugene Braunwald,
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